The information on this site is provided by CodeMap®. CodeMap® remains solely responsible for its content.
The information provided is for general educational purposes only and may not be conclusive or exhaustive.
Recent changes in applicable law, regulations and interpretations may not be reflected in the information contained herein.
For technical questions, please contact CodeMap.
This website is a private website and is not associated, endorsed or authorized by the Department of Health and Human Services, the Center for Medicare and Medicaid Services or any other public or government organization or agency.
|
Healthcare-Associated Infections |
Enteric Infections |
Women's Health & Sexually-Transmitted Infections |
COVID-19 |
Point of Care |
CodeMap®-BD MAX™ System Reimbursement Information
BD MAX™ SYSTEM
Redefine staff productivity with a fully-integrated, automated molecular platform capable of running both IVD and open system assays efficiently and flexibly. |
|
BD MAX™ Individual Assays
|
CPT® Code |
Description |
Medicare Coverage |
NATIONAL LIMIT
Medicare Reimbursement |
NATIONAL LIMIT
Medicaid Reimbursement |
BD MAX™ Cdiff
Clostridioides (Clostridium) difficile toxin B gene (tcdB) in human liquid or soft stool specimens. |
|
87493 |
Infectious agent detection by nucleic acid (DNA or RNA); Clostridium difficile, toxin gene(s), amplified probe technique |
CCI
MUE
|
$ 37.27 |
N/A
|
BD MAX™ MRSA XT
Rapid detection of methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs. |
|
87641 |
Infectious agent detection by nucleic acid (DNA or RNA); Staphylococcus aureus, methicillin resistant, amplified probe technique |
CCI
MUE
|
$ 35.09 |
N/A
|
BD MAX™ StaphSR
Coding for the BD MAX™ StaphSR Assay
Direct detection and differentiation of Staphylococcus aureus (SA) and MRSA DNA from nasal swabs. |
|
87640 |
Infectious agent detection by nucleic acid (DNA or RNA); Staphylococcus aureus, amplified probe technique |
CCI
MUE
|
$ 35.09 (Individual test) |
N/A
(Individual test) |
|
87641-59 |
Infectious agent detection by nucleic acid (DNA or RNA); Staphylococcus aureus, methicillin resistant, amplified probe technique |
CCI
MUE
|
$ 35.09 (Individual test) |
N/A
(Individual test) |
Total Reimbursement: |
$70.18 |
$0.00 |
BD MAX™ CPO assay
Detection and differentiation of the carbapenemase genes blaKPC (Klebsiella pneumoniae carbapenemase),
blaNDM (New Delhi metallo-β-lactamase), blaVIM (Verona integron-encoded metallo-β-lactamase)/blaIMP
(Imipenemase) and blaOXA-48 (Oxacillinase-48 and OXA-48 like variants),
that are associated with carbapenem non-susceptibility in Gram-negative bacteria from rectal swabs. |
|
87798 |
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism |
CCI
MUE
|
$ 35.09 (X 4) |
N/A
(X 4) |
Total Reimbursement: |
$140.36 |
$0.00 |
Becton, Dickinson and Company is not responsible for any actions taken by website users in billing Medicare for Becton, Dickinson and Company products,
equipment or devices, including but not limited to, any billing and/or coding errors. Website users rely on
the information contained in this website at their own risk and should check with the individual Medicare contractors
to verify coverage, coding and payment.
The information contained in this website has been compiled by CodeMap, L.L.C. to assist Becton, Dickinson and Company customers.
CodeMap, L.L.C. remains solely responsible for its content. The information provided is for general educational
purposes only and may not be conclusive or exhaustive. Recent changes in applicable law, regulations and interpretations
may not be reflected in the information contained herein. For technical questions, please contact CodeMap at (847) 381-5465.
CodeMap® has made every reasonable effort to ensure the accuracy of the information contained on
this website. However, the ultimate responsibility for correct coding and claims submission lies with the
provider of services. CodeMap® makes no representation, warranty, or guarantee that this compilation of Medicare information
is error-free or that the use of this information will result in Medicare coverage and subsequent payment of claims.
Final coverage and payment of claims are subject to many factors exclusively controlled by CMS and its contractors.
No part of this web page or data displayed may be redistributed or used without the express written consent of CodeMap®.
CPT copyright 2024 American Medical Association. All rights reserved.
02/05/2025 05:45:06 3.144.72.189
|
|
|